Irinotecan medac inj. 100mg
Irinotecan medac – Used both as monotherapy & in combination with other drugs in first & Second line treatment of advanced and metastatic colorectal cancers. Irinotecan combined with 5-fluorouracil, oxaliplatin and several molecularly-targeted anticancer drugs, resulting in the extension of overall survival.(1)
Irinotecan medac 20mg/ml
Generic Name: Irinotecan hydrochloride trihydrate
Indications
- Monotherapy: For the treatment of advanced colorectal cancer in patients who have failed a prior 5-fluorouracil-containing treatment regimen.
- Combination therapy: With 5-fluorouracil and folinic acid for patients without prior chemotherapy for advanced colorectal cancer.
- With cetuximab: For EGFR-expressing metastatic colorectal cancer following failure of irinotecan-based cytotoxic therapy.
- First-line treatment: In combination with 5-fluorouracil, folinic acid, and bevacizumabfor patients with metastatic carcinoma of the colon or rectum.
Strength
20mg/ml; 100mg/5ml
Pack Size
Single-use vial
Dosage Form
Concentrate for solution for infusion
Categories
Pharmaceuticals
Therapeutic Class
Cytostatics